Drugmaker paying $33M over recalled nonprescription meds

Drugmaker paying $33M over recalled nonprescription meds

Drugmaker paying $33M over recalled nonprescription meds

The $33 million settlement regards the unlawful promotion by McNeil-PPC, Inc. regarding over-the-counter drugs as meeting federal manufacturing standards.

The investigation's findings resulted in the recall of several adulterated McNeil drugs that were initially introduced to the market in batches.

Johnson & Johnson has reached a $33 million settlement with 42 states, resolving allegations the health care giant sold nonprescription medicines that didn't meet federal quality requirements.

"It is vital that the over-the counter-drugs Vermonters take be safe and unadulterated, especially those given to children", said Attorney General Donovan.

Sasheer Zamata exits 'Saturday Night Live'
It has now been revealed that SNL feature Sasheer Zamata will not be returning to Saturday Night Live . The NBC comedy show hired Zamata when the show as being criticized for its lack of ethnic "diversity".

The settlement also includes an agreement that Johnson & Johnson's McNeil Consumer Healthcare unit must follow correct procedures for resolving any manufacturing issues with its nonprescription drugs and may not advertise on its website any product that has had a significant recall within the past year. Class I recalls involve situations in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death.

Pennsylvania and Texas led the Executive Committee, which also included attorneys general from Arizona, Delaware, District of Columbia, Florida, Kentucky, Maryland, Massachusetts, Montana, New Jersey and Ohio.

The settlement was announced Wednesday by attorneys general from the states. Under the terms of the settlement, McNeil will provide the involved Attorneys General with information on wholesalers and warehouses that received the recalled drugs.

This case was handled by Bureau of Consumer Frauds and Protection Chief Jane M. Azia, Deputy Bureau Chief Laura J. Levine and Assistant Attorney General Benjamin J. Lee, under the supervision of the Executive Deputy Attorney General for Economic Justice Manisha M. Sheth.

Related news